Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Thoracic 4Head & Neck 4Gynecologic 4Lymphoid 3Dermatologic 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2CNS 2Tumor-Agnostic 1

Conditions

Lung Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NVP-BKM120 × Gastrointestinal × Clear all
NCT01806649 2021-10-11

BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

Prince of Songkla University

Phase 2 Terminated
5 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡